NVDA
56
-4
HAS
33
3
CVX
47
3
MA
64
7
CPB
30
6
ADSK
70
2
HD
57
2
MTB
67
2
GIS
31
3
SO
53
-4
CFG
70
6
CCI
31
3
GPC
40
3
ROK
62
15
HP
48
3
KMB
39
2
HST
49
-9
LMT
34
2
MAS
58
2
PSA
58
2
NVDA
56
-4
HAS
33
3
CVX
47
3
MA
64
7
CPB
30
6
ADSK
70
2
HD
57
2
MTB
67
2
GIS
31
3
SO
53
-4
CFG
70
6
CCI
31
3
GPC
40
3
ROK
62
15
HP
48
3
KMB
39
2
HST
49
-9
LMT
34
2
MAS
58
2
PSA
58
2
Financhill
Back

Autolus Therapeutics PLC Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
53

AUTL
Autolus Therapeutics PLC

Last Price:
2.95
Seasonality Move:
-10.61%

7 Day Trial

ALL ACCESS PASS

$ 7

Trade on Tuesday. Profit on Friday. Rinse & Repeat

Get the full details now.

Autolus Therapeutics PLC Price Quote

$2.95
+0.01 (+3.87%)
(Updated: November 23, 2024 at 5:26 AM ET)

Autolus Therapeutics PLC Key Stats

Buy
53
Autolus Therapeutics PLC (AUTL) is a Buy
Day range:
$2.76 - $3.05
52-week range:
$2.69 - $7.45
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.64%
Volume:
1.6M
Avg. volume:
2.1M
1-year change:
-34.38%
Market cap:
$782.4M
Revenue:
$1.7M
EPS:
$-1.22

How Much Does Autolus Therapeutics PLC Make?

Data Unavailable

Is Autolus Therapeutics PLC Growing As A Company?

Data Unavailable

Autolus Therapeutics PLC Stock Price Performance

What Is Autolus Therapeutics PLC 52-Week High & Low?

Autolus Therapeutics PLC Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Autolus Therapeutics PLC?

Is Autolus Therapeutics PLC Cash Flow Positive?

  • What Is AUTL Cash Flow From Operations?
    Cash flow from operations (TTM) is -$193.2M
  • What Is Autolus Therapeutics PLC’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $559.6M
  • What Is Autolus Therapeutics PLC’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$12.4M

Autolus Therapeutics PLC Return On Invested Capital

Data Unavailable

Autolus Therapeutics PLC Earnings Date & Stock Price

Autolus Therapeutics PLC Competitors

Autolus Therapeutics PLC Dividend Yield

Autolus Therapeutics PLC Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -41.99%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 10.45
Upside from Last Price: 255.44%

Major Shareholders

  • How many AUTL shares are owned by institutional investors?
    211.5M AUTL shares are owned by institutional investors
  • How many AUTL shares are owned by insiders?
    0 AUTL shares are owned by insiders